Superworth

Prime Medicine price to book ratio PRME

Market value divided by the book value of the company's net assets, since 2023.

Today, Nov 2, 2026
20.2×
4-year median
4.2×
Against its 4-year history
99th
percentile: 0 is its lowest day, 100 its highest
4-year range
1.1× to 21.5×
Peer median
4.9×

Prime Medicine's price to book ratio is 20.2× as of Nov 2, 2026.

That is above its 4-year median of 4.2×, higher than on 99% of days in the last 4 years.

Over that time it ranged from 1.1× in Apr 2025 to 21.5× in Oct 2026.

The median for 4 biotech stocks of a similar size is 4.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far20.2×3.6×21.5×
20253.9×1.1×14.0×
20242.0×2.0×7.9×
20234.4×2.3×5.6×

Against its peers

Companies in Biotechnology nearest Prime Medicine's size, closest first, today.

CompanyPrice to book ratio
PRMEPrime Medicine20.2×
MGTXMeiraGTx4.2×
VCELVericel5.6×
ADMAAdma Biologics6.1×
PLXProtalix BioTherapeutics2.9×
Peer median4.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Prime Medicine

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.